12
RAMBABU AND JAYANTHI
|
tight junction barrier function in ovarian cancer cells. J Biol
Chem. 2005;280:26233‐26240.
1. D'souza T, Indig FE, Morin PJ. Phosphorylation of claudin‐4 by
PKCepsilon regulates tight junction barrier function in ovarian
cancer cells. Exp Cell Res. 2007;313:3364‐3375.
2. Kyuno D, Kojima T, Ito T, et al. Protein kinase Cα inhibitor
enhances the sensitivity of human pancreatic cancer HPAC
cells to Clostridium perfringens enterotoxin via claudin‐4. Cell
Tissue Res. 2011;346:369‐381.
reveals that NCI110039 could be a promising lead for
CLDN4 inhibitory action. Further CLDN4 knockout
studies are required in future to substantiate the mechan-
ism of action of NCI110039 to serve as a potent anticancer
agent.
1
1
ACKNOWLEDGMENTS
1
3. Li J, Chigurupati S, Agarwal R, et al. Possible angiogenic roles for
The authors are thankful for the financial support from
the Department of Science and Technology, Science and
Engineering Research Board (DST‐SERB), DST No:
SB/YS/LS‐299/2013. The authors would like to thank
the management of Vellore Institute of Technology,
Vellore for providing necessary support for carrying out
this study work.
claudin‐4 in ovarian cancer. Cancer BiolTher. 2009;8:1806‐1814.
4. Agarwal R, D'souza T, Morin PJ. Claudin‐3 and claudin‐4
expression in ovarian epithelial cells enhances invasion and is
associated with increased matrix metalloproteinase‐2 activity.
Cancer Res. 2005;65:7378‐7385.
5. Honda H, Pazin MJ, Ji H, Wernyj RP, Morin PJ. Crucial roles of
sp1 and epigenetic modifications in the regulation of the cldn4
promoter in ovarian cancer cells. J Biol Chem. 2006;281:21433‐
1
1
2
1444.
ORCID
16. Kwon MJ, Kim SS, Choi YL, et al. Derepression of cldn3 and cldn4
during ovarian tumorigenesis is associated with loss of repressive
histone modifications. Carcinogenesis. 2010;31:974‐983.
17. Rangel LB, Agarwal R, D'souza T, et al. Tight junction proteins
claudin‐3 and claudin‐4 are frequently overexpressed in ovarian
cancer but not in ovarian cystadenomas. Clin Cancer Res. 2003;9:
2567‐2575.
50
18. Boylan KLM, Misemer B, Derycke M, et al. Claudin 4 is
differentially expressed between ovarian cancer subtypes and
plays a role in spheroid formation. Int J Mol Sci. 2011;12:
.
1
334‐1358.
REFERENCES
1
9. Bellone S, Tassi R, Betti M, et al. Mammaglobin b (scgb2a1) is a
novel tumor rejection antigen and highly differentially ex-
pressed gene in all major histological types of ovarian cancer.
Br J Cancer. 2013;109:462‐471.
20. Patonai A, Erdélyi‐Belle B, Korompay A, et al. Claudins and
tricellulin in fibrolamellar hepatocellular carcinoma. Virchow-
sArchiv. 2011;458:679‐688.
1
. Furuse M, Sasaki H, Fujimoto K, Tsukita S. A single gene
product, claudin‐1 or ‐2, reconstitutes tight junction strands and
recruits occludin in fibroblasts. J Cell Biol. 1998;143:391‐401.
. Tsukita S, Furuse M. Pores in the wall: claudins constitute
tight junction strands containing aqueous pores. J Cell Biol.
2
2
000;149:13‐16.
3
4
5
. Morin PJ. Claudin proteins in human cancer: promising new
targets for diagnosis and therapy. Cancer Res. 2005;65:9603‐9606.
. Singh AB, Sharma A, Dhawan P. Claudin family of proteins
and cancer: an overview. J Oncol. 2010;2010:541957‐541968.
. Ohtani S, Terashima M, Satoh J, et al. Expression of tight‐
junction‐associated proteins in human gastric cancer: down-
regulation of claudin‐4 correlates with tumor aggressiveness
and survival. Gastric Cancer. 2009;12:43‐51.
. Sung CO, Han SY, Kim SH. Low expression of claudin‐4 is
associated with poor prognosis in esophageal squamous cell
carcinoma. Ann Surg Oncol. 2011;18:273‐281.
. Ueda J, Semba S, Chiba H, et al. Heterogeneous expression of
claudin‐4 in human colorectal cancer: decreased claudin‐4
expression at the invasive front correlates cancer invasion and
metastasis. Pathobiology. 2007;74:32‐41.
21. Aravindakshan J, Chen X, Sairam MR. Differential expression
of claudin family proteins in mouse ovarian serous papillary
epithelial adenoma in aging FSH receptor‐deficient mutants.
cessed May 2012.
23. Suzuki H, Nishizawa T, Tani K, et al. Crystal structure of a
claudin provides insight into the architecture of tight junctions.
Science. 2014;344:304‐307.
24. Jorgensen WL, Maxwell DS, Tirado‐Rives J. Development and
testing of the OPLS all‐tom force field on conformational
energetics and properties of organic liquids. J Am Chem Soc.
1996;118:11225‐11236.
25. Kaminski GA, Friesner RA, Tirado‐Rives J, Jorgensen WL.
Evaluation and reparameterization of the OPLS‐AA force
field for proteins via comparison with accurate quantum
chemical calculations on peptides. J Phys Chem B. 2001;105:
6474‐6487.
6
7
8
. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular
spheroids in ovarian cancer metastases: biology and pathology.
Gynecol Oncol. 2009;113:143‐148.
9
. Boyle P, Levin B. World Cancer Report 2008. France: Interna-
26. Jorgensen WL. The many roles of computation in drug
tional Agency for Research on Cancer; 2008.
0. D'Souza T, Agarwal R, Morin PJ. Phosphorylation of claudin‐3
discovery. Science. 2004;303:1813‐1818.
27. Song CM, Lim SJ, Tong JC. Recent advances in computer‐aided
drug design. Brief Bioinform. 2009;10:579‐591.
1
at threonine 192 by cAMP‐dependent protein kinase regulates